#stock-performance

#stock-performance

Humana's surge reflects a stack of catalysts centered on Medicare Advantage (MA). A favorable MA rate decision earlier this year lifted a major regulatory overhang, and Humana's concentrated MA exposure means it benefits more than diversified peers. Bernstein recently raised its price target on the stock to $288 from $211, citing improved MA final rates and positive Q1 utilization signals.

Baidu (BIDU) stock climbed higher early Monday after the Chinese search engine company reported first-quarter results ahead of analyst expectations. The company touted the growth of its AI cloud offering as its advertising business continued to slow.

Investors are watching Figma ( NYSE:FIG) ahead of first-quarter results due after the close today, Thursday, May 14, at 4:05 PM EST. The bar is unusually high tonight with the stock up 6% today.

Plug Power reported Q1 2026 revenue of $163.51 million, up 22% year over year (YoY) and beating the $139.76 million consensus. Adjusted EPS came in at -$0.08 versus the -$0.1033 estimate. Plug Power's GAAP gross margin improved to -13% from -55% in the prior-year quarter, a 42 percentage point swing. CEO Jose Luis Crespo stated, "Our first quarter results reflect strong commercial execution and continued progress improving the underlying economics of the business and positions us to achieve our EBITDAS positive target in Q4 2026."

Clorox ( NYSE: CLX | CLX Price Prediction) spent the past 10 years doing what consumer staples are supposed to do: pay reliably, raise dividends annually, and grind through cycles. The pandemic briefly turned cleaning brands into pantry essentials, sending shares above prior highs. Then came margin compression, a 2023 cyberattack, and an ambitious $580 million ERP overhaul that the company finished rolling out in winter of FY2026.

Investors are watching whether Axon 2.0 continues to boost ad performance, and whether management signals continued strength into the rest of 2026.

Rivian entered April with renewed liquidity and a tangible product catalyst, receiving a $1 billion equity tranche from Volkswagen and a $4.5 billion loan from the Department of Energy, easing cash concerns that had pressured the stock for quarters.

The CBOE Volatility Index (^VIX) has shed nearly 30% over the past month, falling from a 12-month high of just over 31 in late March to a reading inside the normal range.

Both companies face shared headwinds: reciprocal tariff impacts running at roughly 5 percentage points of margin pressure, softening European demand, and a fiercely competitive solar inverter market.

Guggenheim analyst Seamus Fernandez raised his firm's price target on AstraZeneca to 16,500 GBp from 16,000 GBp, maintaining a Buy rating after updating the firm's model ahead of Q1 earnings.

Morgan Stanley analyst Tim Hsiao has kept his Overweight rating intact while cutting his price target to $22 from $26, implying meaningful upside from the current price of $17.58. That $22 target sits just above Street consensus, signaling Morgan Stanley remains among the more constructive voices on the name.

Citi's thesis centers on two catalysts converging at the right time. Data center spending and a constructive Pennsylvania rate case are seen driving accelerating earnings growth through 2026 and beyond.

UBS sees scope for further upside in nitrogen pricing and earnings, with the current industry disruption more severe than what is reflected in gas and nitrogen pricing at present.

BTIG rates FTAI a Buy, raising its target from $335 to $340. The firm acknowledges FTAI missed Q4 EBITDA relative to consensus but argues the 2026 setup remains attractive.